[go: up one dir, main page]

AU2001264079A1 - Lipids for modulating immune response - Google Patents

Lipids for modulating immune response

Info

Publication number
AU2001264079A1
AU2001264079A1 AU2001264079A AU6407901A AU2001264079A1 AU 2001264079 A1 AU2001264079 A1 AU 2001264079A1 AU 2001264079 A AU2001264079 A AU 2001264079A AU 6407901 A AU6407901 A AU 6407901A AU 2001264079 A1 AU2001264079 A1 AU 2001264079A1
Authority
AU
Australia
Prior art keywords
lipids
fatty acids
glycerol
immune response
acyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001264079A
Inventor
William Leslie Porter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0014437.8A external-priority patent/GB0014437D0/en
Priority claimed from GB0026667A external-priority patent/GB0026667D0/en
Priority claimed from GB0028239A external-priority patent/GB0028239D0/en
Application filed by Individual filed Critical Individual
Publication of AU2001264079A1 publication Critical patent/AU2001264079A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A product and the use thereof to stimulate and/or modulate immune response in animals and humans, comprising lipids having a glycerol backbone carrying at least one alkyl or acyl chain, wherein the lipid is phospholipid, glycolipid or neutral lipid, saturated or unsaturated, and the number of carbon atoms in the hydrocarbon tails lies between (10 and 22) inclusive, the lipids being defined as esters of glycerol (propane 1,2,3-triol) with fatty acids, also including 1,2-di-<i>O</i>-acylglycerol joined at oxygen (3) by a glycosidic linkage to a carbohydrate, also derivatives of glycerol in which one hydroxy group, commonly but not necessarly primary, is esterified with fatty acids, and execluding those organic compounds consisting of a trisaccharide repeating unit with oligosaccharide side chains and acyl or amine linked fatty acids.
AU2001264079A 2000-06-14 2001-06-13 Lipids for modulating immune response Abandoned AU2001264079A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0014437 2000-06-14
GBGB0014437.8A GB0014437D0 (en) 2000-06-14 2000-06-14 Immune response stimulation
GB0026667 2000-11-01
GB0026667A GB0026667D0 (en) 2000-11-01 2000-11-01 Lipids promoting immune response
GB0028239A GB0028239D0 (en) 2000-11-20 2000-11-20 Lipids modulating immune response
GB0028239 2000-11-20
PCT/GB2001/002568 WO2001095914A1 (en) 2000-06-14 2001-06-13 Lipids for modulating immune response

Publications (1)

Publication Number Publication Date
AU2001264079A1 true AU2001264079A1 (en) 2001-12-24

Family

ID=27255760

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001264079A Abandoned AU2001264079A1 (en) 2000-06-14 2001-06-13 Lipids for modulating immune response

Country Status (5)

Country Link
EP (1) EP1289530B1 (en)
AT (1) ATE341331T1 (en)
AU (1) AU2001264079A1 (en)
DE (1) DE60123603T2 (en)
WO (1) WO2001095914A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
EP1900364B1 (en) * 2001-04-18 2013-09-25 ProMetic BioSciences Inc. Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
CN100427081C (en) 2003-02-07 2008-10-22 普罗米蒂克生物科学公司 Medium-chain fatty acids, glycerides and analogues as erythropoiesis-stimulating agents
AU2016256979B2 (en) 2015-05-04 2021-01-28 Versantis AG Method for preparing transmembrane pH-gradient vesicles
EP3468551A4 (en) 2016-06-08 2020-01-22 Sunregen Healthcare AG Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
BR112020004023A2 (en) * 2017-09-12 2020-09-08 Sunregen Healthcare Ag use of a compound and pharmaceutical composition or nutritional supplement
GB201718741D0 (en) 2017-11-13 2017-12-27 Davies Professor Tony Constructs comprising fatty acids

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57145810A (en) * 1982-02-01 1982-09-09 Toyama Chem Co Ltd Immunological activator containing lysophospholipid and preparation thereof
US4978654A (en) * 1984-04-16 1990-12-18 Board Of Regents, The University Of Texas System Composition and method for treatment of disseminated fungal infections in mammals
SE9101642D0 (en) * 1991-05-30 1991-05-30 Kabi Pharmacia Ab phospholipids
IL121322A (en) * 1997-07-16 2002-07-25 Modus Biolog Membranes Ltd Lipid-based immune modulator pharmaceutical compositions and their preparation
GB9930862D0 (en) * 1999-12-29 2000-02-16 Porter William L Immune response stimulation

Also Published As

Publication number Publication date
EP1289530B1 (en) 2006-10-04
EP1289530A1 (en) 2003-03-12
DE60123603D1 (en) 2006-11-16
ATE341331T1 (en) 2006-10-15
WO2001095914A1 (en) 2001-12-20
DE60123603T2 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
BR9807443A (en) Processes for reducing the incidence of necrotic enterocolitis in a child and for the production of an enteral formula, and, improved enteral formulas containing arachidonic acid and docosahexaenoic acid and suitable for feeding children.
CA2101274A1 (en) Microbial oil mixtures and uses thereof
Kanai et al. Antibacterial and cytotoxic aspects of longchain fatty acids as cell surface events: Selected topics
ID21473A (en) PHARMACEUTICAL PRICES CONTAINING EICOSAPENTANOIC ACID AND STEARIDONIC ACID
KR960017617A (en) Salicylic Acid Derivatives Used as Stabilizers in Oil-in-water Emulsions
PL306587A1 (en) Cosmetic and/or dermatological composition containing salicylic acid derivatives and method of stabilising such derivatives
PT669809E (en) PROCESS FOR THE HETEROTROPIC PRODUCTION OF MICROBIAL PRODUCTS WITH HIGH CONCENTRATIONS OF HIGHLY INSATURATED FATTY ACIDS OMEGA-3
NZ331084A (en) Enteral formula or nutritional supplement containing arachidonic and docosahexaenoic acids
ES2013792A6 (en) External agent for skin
ES2069244T3 (en) COSMETIC, PHARMACEUTICAL OR FOOD COMPOSITION THAT INCLUDES LIPIDIC VESICLES.
NO951601D0 (en) Solid non-digestible polyol polyesters containing esterified hydroxy fatty acids such as esterified castor oleic acid
BR0009340B1 (en) composition suitable for use on the skin or hair, product for application on the skin or hair, method of preparing a composition suitable for application on the skin or hair, and use of a composition.
MY107327A (en) Aqueous cosmetic composition and preparation method thereof.
AU2001264079A1 (en) Lipids for modulating immune response
AU7460987A (en) Skin tanning composition
TR199801784T2 (en) Kuma� yumu�atma bile�i�i / bile�imi.
ATE201961T1 (en) TRIGLYCERIDES RICH IN POLYUNSATURATED FATTY ACIDS
MY111244A (en) Novel solid, nondigestible, fat-like compounds and food compositions containing same.
KR970014571A (en) Synergistic Antimicrobial Composition of 1,2-Dibromo-2,4-dicyanobutane and Parahydroxybenzoic Acid Ester
GB9930862D0 (en) Immune response stimulation
ES2113738T3 (en) PROCEDURE FOR MAKING SOLUBLE ORGANIC COMPOUNDS IN FAT SYSTEMS, NEW CHEMICAL COMPLEXES OF SUCH COMPOUNDS AND VARIOUS APPLICATIONS OF THE COMPLEXES.
WO2003056928A1 (en) Fat and oil compositions for decreasing blood lipid
AU2003240187A1 (en) A process for preparing long chain saturated or unsaturated oxygenated compounds
ONO et al. Concentration of docosahexaenoic acid-containing phospholipid through Lipozyme IM-mediated hydrolysis
KR970701531A (en) ANTI-ACNE COMPOSITIONS